In January 2020, following a pneumonia of unknown etiology, WHO announced the state of emergency which would mark the beginning of the Covid-19 pandemic, caused by SARS CoV-2 virus responsible for the infection of respiratory tract. Once made freely available the viral genome sequence and structural characteristics, molecular tests (PCR) and immunological tests were developed quickly to identify infected subjects. In December 2021, BioNTech and Moderna companies developed and received the AIC for Comirnaty and Spikevax, two slightly different mRNA-based vaccines which encoded the spike protein encapsulated in liposomes. The earliest people vaccinated were those most at risk: public and private health care personnel, RSA staff, workers with a higher risk of being infected and immunocompromised people. The employees of City of Health of Turin and Asl TO3 were among the first, and thanks to the questionnaires completed for the first and second dose related to pharmacovigilance, it was possible to collect and classify the adverse events (ADRs) developed by the vaccinated subjects. This study describes the developed diseases, severity, occurrence and outcome of adverse reactions in the mentioned personnel after the first and second dose. The results obtained indicate that out of 11824 vaccinated subjects with a second dose, 11.79% developed common reactions such as general pain due to the site of administration, fatigue, joint pain, muscle pain, musculoskeletal system pathologies, nervous system, and gastrointestinal complications. The final picture that emerges from this study strongly demomstrates that administration of mRNA vaccines is clearly favorable from a benefit/risk perspective and does not result in the occurrence of serious side effects in the population vaccinated with a second dose.
Nel gennaio del 2020, a seguito di una pneumonia di etiologia ignota il WHO proclama lo stato di emergenza che segnerà l'inizio della pandemia covid-19, causata da SARS Cov-2, virus appartenete alla famiglia dei Sars, responsabili di infezioni del tratto respiratorio. Quindi si è rivelato necessario studiare la genetica, le caratteristiche strutturali e lo sviluppo di test molecolari (PCR) e test immunologici per individuare i soggetti infettati. Nel dicembre del 2021 le aziende BioN-tech e Moderna sviluppano e ricevono l'AIC di Comirnaty e Spikevax, vaccini a base di mRNA che codifica per la proteina spike incapsulato in liposomi. I primi vaccinati sono state le figure più a rischio: personale sanitario pubblico e privato, personale delle RSA, lavoratori con un maggior rischio di essere contagiati e persone immunocompromesse. I dipendenti di Città della Salute di Torino e di Asl TO3 sono stati tra i primi e grazie ai questionari compilati per le I e II dosi legati alla farmacovigilanza si sono potuto raccogliere e classificare gli eventi avversi (ADR) sviluppati dai vaccinati. Lo studio in esame descrive le patologie sviluppate, la gravità, l'insorgenza e l'esito delle reazioni avverse nel personale citato dopo Ia e IIa dose. I risultati ottenuti indicano che su 11824 vaccinati l’11.79% ha sviluppato delle reazioni, tra le comuni quali dolori generali dovuto alla sede di somministrazione, stanchezza, dolori articolari, dolori muscolari, patologie del sistema muscolo scheletrico, sistema nervoso e complicazioni gastro intestinali. Il quadro finale che emerge da questo studio indica che la somministrazione di vaccini a mRNA è nettamente favorevole dal punto di vista beneficio/rischio e non comporta l’insorgenza di gravi effetti collaterali nella popolazione vaccinata con una seconda dose.
ANALISI DI EVENTI AVVERSI (ADR) INDOTTI DA VACCINI A mRNA NEL PERSONALE MEDICO DELLA CITTA’ DI TORINO
RAVERA, DAVIDE LINO
2021/2022
Abstract
In January 2020, following a pneumonia of unknown etiology, WHO announced the state of emergency which would mark the beginning of the Covid-19 pandemic, caused by SARS CoV-2 virus responsible for the infection of respiratory tract. Once made freely available the viral genome sequence and structural characteristics, molecular tests (PCR) and immunological tests were developed quickly to identify infected subjects. In December 2021, BioNTech and Moderna companies developed and received the AIC for Comirnaty and Spikevax, two slightly different mRNA-based vaccines which encoded the spike protein encapsulated in liposomes. The earliest people vaccinated were those most at risk: public and private health care personnel, RSA staff, workers with a higher risk of being infected and immunocompromised people. The employees of City of Health of Turin and Asl TO3 were among the first, and thanks to the questionnaires completed for the first and second dose related to pharmacovigilance, it was possible to collect and classify the adverse events (ADRs) developed by the vaccinated subjects. This study describes the developed diseases, severity, occurrence and outcome of adverse reactions in the mentioned personnel after the first and second dose. The results obtained indicate that out of 11824 vaccinated subjects with a second dose, 11.79% developed common reactions such as general pain due to the site of administration, fatigue, joint pain, muscle pain, musculoskeletal system pathologies, nervous system, and gastrointestinal complications. The final picture that emerges from this study strongly demomstrates that administration of mRNA vaccines is clearly favorable from a benefit/risk perspective and does not result in the occurrence of serious side effects in the population vaccinated with a second dose.È consentito all'utente scaricare e condividere i documenti disponibili a testo pieno in UNITESI UNIPV nel rispetto della licenza Creative Commons del tipo CC BY NC ND.
Per maggiori informazioni e per verifiche sull'eventuale disponibilità del file scrivere a: unitesi@unipv.it.
https://hdl.handle.net/20.500.14239/15843